亚辉龙11月21日获融资买入1253.69万元，融资余额4.43亿元

Group 1 - The core point of the news is that Aihua Long's stock price dropped by 3.68% on November 21, with a trading volume of 99.95 million yuan, indicating a negative market sentiment towards the company [1] - On November 21, Aihua Long had a financing buy-in amount of 12.54 million yuan and a financing repayment of 15.79 million yuan, resulting in a net financing buy of -3.25 million yuan [1] - As of November 21, the total balance of margin trading for Aihua Long was 445 million yuan, with the financing balance accounting for 5.21% of the circulating market value, indicating a high level compared to the past year [1] Group 2 - Aihua Long, established on September 17, 2008, specializes in the research, production, and sales of in vitro diagnostic instruments and related reagents, with a significant portion of its revenue coming from self-produced reagents (58.57%) [2] - For the period from January to September 2025, Aihua Long reported an operating income of 1.287 billion yuan, a year-on-year decrease of 7.69%, and a net profit attributable to shareholders of 60.42 million yuan, down 72.36% year-on-year [2] - As of September 30, 2025, Aihua Long had 12,800 shareholders, an increase of 7.40% from the previous period, while the average circulating shares per person decreased by 6.89% to 44,595 shares [2] Group 3 - Aihua Long has distributed a total of 693 million yuan in dividends since its A-share listing, with 531 million yuan distributed over the past three years [3] - As of September 30, 2025, the seventh largest circulating shareholder of Aihua Long was Huabao Zhongzheng Medical ETF, holding 9.6516 million shares, which is a decrease of 1.7669 million shares compared to the previous period [3]